Related Experiment Video
Updated: Jul 1, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Pharmacogenetic relevance of MTHFR polymorphisms
Giuseppe Toffoli1, Elena De Mattia
1Experimental and Clinical Pharmacology Unit, CRO National Cancer Institute via Franco Gallini, 2, 33081 Aviano (PN), Italy. gtoffoli@cro.it
Pharmacogenomics
|September 11, 2008
Summary
The 5,10-methylenetetrahydrofolate reductase (MTHFR) enzyme
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- The 5,10-methylenetetrahydrofolate reductase (MTHFR) enzyme is crucial for folate metabolism.
- Common MTHFR gene polymorphisms (C677T, A1298C) are linked to reduced enzyme activity and cancer risk.
- These polymorphisms may influence the effectiveness and toxicity of certain cancer and rheumatoid arthritis drugs.
Purpose of the Study:
- To explore the role of MTHFR polymorphisms in cancer susceptibility.
- To investigate the pharmacogenetic implications of MTHFR variants in drug response.
- To assess the combined effects of MTHFR polymorphisms and potential interactions.
Main Methods:
- Analysis of MTHFR C677T and A1298C polymorphisms.
- Evaluation of enzyme activity and association with cancer risk.
- Assessment of MTHFR variants' impact on fluoropyrimidine and antifolate therapy.
- Consideration of combined polymorphisms, haplotype analysis, and gene-environment interactions.
Main Results:
- MTHFR polymorphisms are associated with altered enzyme activity and cancer susceptibility.
- C677T and A1298C variants influence the efficacy and toxicity of antifolate drugs.
- Combined polymorphism and haplotype analyses may offer improved predictive value.
- Gene-nutrient, gene-environmental, and gene-racial/ethnic interactions modulate MTHFR variant effects.
Conclusions:
- MTHFR polymorphisms play a significant role in cancer risk and drug response.
- Pharmacogenetic analysis of MTHFR variants is important for personalized medicine.
- Further research is needed to establish genotype-based dosing recommendations.
- Understanding MTHFR genetic variations can optimize treatment strategies for cancer and rheumatoid arthritis.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...